Clinical application of thioredoxin reductase as a novel biomarker in liver cancer

Abstract Hepatic cancer is often amenable to surgery, including percutaneous ablation, trans-arterial chemoembolization. However, in metastatic cases, surgery is often not an effective option. Chemotherapy as a conventional clinical method for treatment of malignant diseases may be useful in such ca...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Xuping Wu, Qi Wang, Yousheng Lu, Jinye Zhang, Hanwei Yin, Yongxiang Yi
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/ea2342db5ee242668d9b3e5263a5e4c3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ea2342db5ee242668d9b3e5263a5e4c3
record_format	dspace
spelling	oai:doaj.org-article:ea2342db5ee242668d9b3e5263a5e4c32021-12-02T11:39:43ZClinical application of thioredoxin reductase as a novel biomarker in liver cancer10.1038/s41598-021-85688-32045-2322https://doaj.org/article/ea2342db5ee242668d9b3e5263a5e4c32021-03-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-85688-3https://doaj.org/toc/2045-2322Abstract Hepatic cancer is often amenable to surgery, including percutaneous ablation, trans-arterial chemoembolization. However, in metastatic cases, surgery is often not an effective option. Chemotherapy as a conventional clinical method for treatment of malignant diseases may be useful in such cases, but it is likewise not always able to slow or halt progression, therefore novel approaches for treatment of hepatic cancer are needed. Current research suggests that molecular tumor markers (TM) can play a crucial role for diagnosis and prognostic evaluation of malignancies, and TM such as AFP, CEA, CA19-9 have been reported in many malignant diseases. Thioredoxin reductase (TrxR), a type of anti-oxidant biomarker, has become a TM of significant interest. However, little is known about the above TM and TrxR activity in liver cancer. Therefore, this paper aimed to assess these TM with regards to diagnosis and and monitoring treatment efficacy in both primary and metastatic liver cancer. Our results showed TrxR had superior performance for discriminating between liver cancer patients and healthy controls than AFP, CEA, and CA19-9. TrxR also exhibited superior performance for assessing benefits of chemotherapy regardless if patients had PLC or MLC. Meanwhile, due to diagnostic efficiency of unresponsive chemotherapy patients, TrxR also showed a higher activity levels than other general markers in liver metastasis patients. Our results suggest that application of TrxR in combination with other tumor markers may maximize the efficiency of diagnosis and assessment of therapeutic efficiency, and provide new insights for the clinical application of TrxR as a candidate biomarker for liver cancer.Xuping WuQi WangYousheng LuJinye ZhangHanwei YinYongxiang YiNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Xuping Wu Qi Wang Yousheng Lu Jinye Zhang Hanwei Yin Yongxiang Yi Clinical application of thioredoxin reductase as a novel biomarker in liver cancer
description	Abstract Hepatic cancer is often amenable to surgery, including percutaneous ablation, trans-arterial chemoembolization. However, in metastatic cases, surgery is often not an effective option. Chemotherapy as a conventional clinical method for treatment of malignant diseases may be useful in such cases, but it is likewise not always able to slow or halt progression, therefore novel approaches for treatment of hepatic cancer are needed. Current research suggests that molecular tumor markers (TM) can play a crucial role for diagnosis and prognostic evaluation of malignancies, and TM such as AFP, CEA, CA19-9 have been reported in many malignant diseases. Thioredoxin reductase (TrxR), a type of anti-oxidant biomarker, has become a TM of significant interest. However, little is known about the above TM and TrxR activity in liver cancer. Therefore, this paper aimed to assess these TM with regards to diagnosis and and monitoring treatment efficacy in both primary and metastatic liver cancer. Our results showed TrxR had superior performance for discriminating between liver cancer patients and healthy controls than AFP, CEA, and CA19-9. TrxR also exhibited superior performance for assessing benefits of chemotherapy regardless if patients had PLC or MLC. Meanwhile, due to diagnostic efficiency of unresponsive chemotherapy patients, TrxR also showed a higher activity levels than other general markers in liver metastasis patients. Our results suggest that application of TrxR in combination with other tumor markers may maximize the efficiency of diagnosis and assessment of therapeutic efficiency, and provide new insights for the clinical application of TrxR as a candidate biomarker for liver cancer.
format	article
author	Xuping Wu Qi Wang Yousheng Lu Jinye Zhang Hanwei Yin Yongxiang Yi
author_facet	Xuping Wu Qi Wang Yousheng Lu Jinye Zhang Hanwei Yin Yongxiang Yi
author_sort	Xuping Wu
title	Clinical application of thioredoxin reductase as a novel biomarker in liver cancer
title_short	Clinical application of thioredoxin reductase as a novel biomarker in liver cancer
title_full	Clinical application of thioredoxin reductase as a novel biomarker in liver cancer
title_fullStr	Clinical application of thioredoxin reductase as a novel biomarker in liver cancer
title_full_unstemmed	Clinical application of thioredoxin reductase as a novel biomarker in liver cancer
title_sort	clinical application of thioredoxin reductase as a novel biomarker in liver cancer
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/ea2342db5ee242668d9b3e5263a5e4c3
work_keys_str_mv	AT xupingwu clinicalapplicationofthioredoxinreductaseasanovelbiomarkerinlivercancer AT qiwang clinicalapplicationofthioredoxinreductaseasanovelbiomarkerinlivercancer AT youshenglu clinicalapplicationofthioredoxinreductaseasanovelbiomarkerinlivercancer AT jinyezhang clinicalapplicationofthioredoxinreductaseasanovelbiomarkerinlivercancer AT hanweiyin clinicalapplicationofthioredoxinreductaseasanovelbiomarkerinlivercancer AT yongxiangyi clinicalapplicationofthioredoxinreductaseasanovelbiomarkerinlivercancer
_version_	1718395735646404608

Clinical application of thioredoxin reductase as a novel biomarker in liver cancer

Ejemplares similares